symyoo

SYMYOO, Leading the Way in Digitalized Clinical Research

SYMYOO is on track to become the most digitalized CRO by integrating advanced IT solutions into its home-grown EDC/ Clinical Trial Management System, in order to streamline patient recruitment and to boost trial efficiency. By combining proprietary digital systems with expert personnel, Symyoo has successfully launched the Man-Unmanned Teaming Clinical Trial (MUM-T CT) model, driving innovation SYMYOO, Leading the Way in Digitalized Clinical Research

Back to list

SYMYOO Supports Korea Diabetes Association (KDA)’s large-scale RRCT, REMATCH

As a National Coordination Center, SYMYOO conducts REMATCH study, which is a very large-scale Registry-based Randomized Clinical Trial (RRCT) sponsored by the Korea Diabetes Association (KDA). This REMATCH study aims to define optimal type 2 diabetes management strategies that will improve cardiovascular and renal outcomes in type 2 diabetes mellitus patient population. Over 60 clinical SYMYOO Supports Korea Diabetes Association (KDA)’s large-scale RRCT, REMATCH

Back to list

Launch of SYNeRAᵀᴹ Platform DB Engine

Smart Trial Research Center (STRC) at SYMYOO launches a new database engine, developed with multi-tier system architecture, meta-data driven and hierarchically structured database design. This SYNeRAᵀᴹ DB engine is optimized considering the systemic structural characteristics that easily reflect various system requirements from simple clinical studies to large-scale, multinational, and multi-center late-stage clinical trials, while enabling Launch of SYNeRAᵀᴹ Platform DB Engine

Back to list

Dodlab, an IT Platform Company Launched

Symyoo established Dodlab, Inc., to create new innovations and values under the vision ‘Making the Better Place to Live with IT Technologies’. Dodlab will pioneer new areas in the many industrial sectors, including the healthcare arena, and develop into a leading IT technology company with excellence in technology and expertise in order to help their Dodlab, an IT Platform Company Launched

Back to list

Global Coordinating Center For Late Phase Covid-19 Trials

Symyoo was designated as a global coordinating center to run late phase multinational clinical trials for Covid-19 medication development. The trials are conducted widely across Korea and European countries. Symyoo understands well that the trial operations should be very specific to the risk and complexity of each region/country where the trials are conducted.

Back to list

SYMYOO America, Inc. Established

Established Symyoo America, Inc. in order to provide global trial consulting services for the Korean pharmaceutical, biotechnology and life-science companies wishing to enter the global market.

Back to list

Korea CDISC Coordinating Committee (K3C), CDISC/SDTM Industry Partner

Symyoo participated in Korea CDISC Coordinating Committee (K3C) and achieved CDISC/SCDM industry partnership, which is granted to a company having comprehensive data management capability for clinical research.

Back to list

IWRS, RBM Integration Into SYMYOO EDC, SYNeRA™

Symyoo EDC system, SYNeRA™, expanded its functionalities by integrating new modules, including IWRS (Interactive Web-based Randomization System), IP Accountability (Investigational Product Tracking and Management System), and RBM (Risk-Based Monitoring System). Symyoo IWRS can handle various randomization algorithms from simple permuted block randomization to very complex covariate adaptive randomization (biased coin, minimum sufficient).

Back to list

150+ Trials And 30th Oncology Trial On SYMYOO’s 9th Anniversary

Conducted more than 150 clinical studies, including 30 oncology trials over 9 years since its foundation in 2009. Symyoo had been coordinating and collaborating with various

Back to list

Introducing SYMYOO EDC, SYNeRA™

Launched Symyoo EDC system, SYNeRA™ for clinical research data collection and management. Symyoo SMART TRIALS research center continues to develop and expand SYNeRA™ functionalities into a web-based Comprehensive Clinical Trial Management System.

Back to list